Katia Bencardino - Concepedia

Author

Katia Bencardino

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda ORCID

Also Known As

K Bencardino, K. BENCARDINO, K. Bencardino, Katia B. Bencardino, Katia Bencardino, Katia Bruna Bencardino

152

Publications

7.8K

Citations

H-Index

Concepts

All Affiliations

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda Istituti di Ricovero e Cura a Carattere Scientifico Candiolo Cancer Institute University of Milan Istituto Oncologico Veneto

About

Katia Bencardino is an author at Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda specializing in medicine, oncology, and colorectal cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	21	4.3K
2	Cell Biology	3	3	149
3	Health Sciences	2	2	46
4	Gastroenterology	2	2	330
5	Hepatology	1	1	21

Katia Bencardino

Publications

Citations

H-Index

Page 1

	Year	Citations
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Sandra Misale, Rona Yaeger, Sebastijan Hobor, Nature Kras MutationsMedicineColorectal CancerPathologyAnti-egfr Therapy	2012	1.9K
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino, The Lancet Oncology OncologyMedicinePathologyColorectal CancerDual-targeted Therapy	2016	984
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1) Alexander Drilon, Salvatore Siena, Sai‐Hong Ignatius Ou, Cancer Discovery	2017	795
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer Fotios Loupakis, Annamaria Ruzzo, Chiara Cremolini, British Journal of Cancer	2009	557
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study Emanuele Valtorta, Cosimo Martino, Andrea Sartore‐Bianchi, Modern Pathology Her2 Scoring SystemColorectal SurgeryMedicineGastroenterologyColorectal Cancer	2015	309
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer Alessio Amatu, Andrea Sartore‐Bianchi, Katia Bencardino, Annals of Oncology	2019	290
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer Sandra Misale, Sabrina Arena, Simona Lamba, Science Translational Medicine	2014	267
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients Federico Cappuzzo, Giovanna Finocchiaro, Elisa Rossi, Annals of Oncology Egfr FishMedicineColorectal CancerPathologyCancer Treatment	2007	267
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer Ludovic Barault, Alessio Amatu, Giulia Siravegna, Gut	2017	231
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial Andrea Sartore‐Bianchi, Sara Lonardi, Cosimo Martino, ESMO Open OncologyColorectal CancerPathologyCancer TreatmentMedicine	2020	175

Page 1